PENTASA IN THE TREATMENT OF NONSPECIFIC ULCERATIVE COLITIS AND CROHN’S DISEASE
- Authors: Krylova I.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Issue: Vol 25, No 1 (2014)
- Pages: 35-36
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115898
- ID: 115898
Cite item
Open Access
Access granted
Abstract
The paper analyzes the new Pentasa formulation rectal suppositories in a dose of 1 g. The pharmacokinetic properties of Pentasa tablets and rectal suppositories are compared. A comfortable dosage regimen for suppositories is recommended: 1 g before going to sleep.
Full Text
About the authors
I. Krylova
I.M. Sechenov First Moscow State Medical University
Email: krylirina@gmail.com
MD
References
- Адлер Г. Болезнь Крона и язвенный колит / М.: ГЭОТАР-Медицина, 2001; 527.
- Златкина А.Р. Лечение хронических болезней органов пищеварения / М., 1994; с. 163-217.
- Логинов А.С., Парфенов А.И. Болезни кишечника / М., 2000; с. 32.
- Рысс В.С., Фишзон-Рысс Ю.И. Некоторые особенности клинической картины и лечения неспецифического язвенного колита и болезни Крона // Тер. арх. - 1990; 2: 25-32.
- Eaden J., Abrams K., Mayberry J. The true risk of colorectal cancer in ulcerative colitis: a meta-analysis // Castroenterology. - 1999; 116: 398.
- Gionchetti P., Rizzello F., Venturi A. et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis // Aliment. Pharmacol. Ther. - 1997; 11: 1053-7.
- James S., Irving P., Gearry R. et al. Management of distal ulcerative colitis: frequently asked questions analysis // Intern. Med. J. - 2008; 38: 114-9.
- Hanauer S., Schwartz J., Robinson M. et al. Mesalamine capsules for treatment of active ulcerative colitis. Result of a controlled trial // Am. J. Gastroenterol. - 1993; 88: 1188-97.
- Kaiser G., Yan F., Polk D. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor jB activation in mouse colonocytes // Gastroenterology. - 1999; 116: 602-9.
- Kleo U., Maier K., Fischer C. et al. A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics // Arzneim. Forsch. - 1985; 35: 636-9.
- Layer P., Goebell H., Keller J. et al. Delivery and fate of oral mesalamine microgranules within the human small intestine // Gastroenterology. - 1995; 108: 1427-33.
- Marteau P., Probert C., Lindgren S. et al. Combined oral and enema treatment with 5-aminosalicylic in distal ulcerative colitis: a randomized, double blind, placebo controlled study // Gut. - 2005; 54: 960-5.
- Vree T., Dammers E., Exler P. et al. Liver and gut mucosa acetylation of mesalazine in healthy volunteers // Int. J. Clin. Pharmacol. Ther. - 2000; 38: 514-22.
Supplementary files
